drugset / Trial / NCT05258565

TPA in Acute Stroke With COVID Verus Non-COVID-19 Patients

NCT05258565

Non-randomizedSequentialTriple-blindTreatment

Summary

The investigator will recruit consecutively all patients coming with acute ischemic stroke either with or without COVID -19 infection and suitable for IV injection with Tissue plasminogen activators according to guideline and inclusion criteria of tPA. Aswan University Hospital.

Timeline

Start
2022-03-01
Primary completion
2022-06-15
Completion
2022-09-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous

Indications